Growth DisordersNCT05242224
Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development
A study testing Evolutionary Nutrition Package in people with Growth Disorders and Malnutrition, Fetal, run by Washington University School of Medicine at 1 site in Ecuador.
Trial summary
Globally, 250 million children do not reach their developmental potential and 155 million are stunted, yet few population-based studies have examined the direct effects of nutrient deficiencies on early brain development. Read more about this study
- Who is it for?
- Ages 18 years and older, women onlyHealthy volunteers can take part
- Conditions the study is for
- Growth Disorders, Malnutrition, Fetal, Stunting
- What is being tested?
- Evolutionary Nutrition Package
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteEcuador
- Study dates
- 5 Jan 2022to Jun 2025
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Women only
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- healthy
- in their first trimester
- carrying a singleton pregnancy
Who cannot join
- less than 18 years of age
- have a chronic health condition (HIV, TB, epilepsy, etc.)
- have a multiple pregnancy (twins, triplets, etc.)
- intend to move away from the study area
- have known allergies to eggs or fish
- have a blood pressure greater than 160/100
Trial locations and contacts
1 site in 1 country.
About this study
Globally, 250 million children do not reach their developmental potential and 155 million are stunted, yet few population-based studies have examined the direct effects of nutrient deficiencies on early brain development. This study will examine an evolutionary nutrition intervention during pregnancy derived from diets consumed for 99.9% of hominin history when bodies and brains were healthier. A pilot clinical trial will be conducted in the central highlands of Ecuador to compare fetal and newborn outcomes among women randomized to: 1) evolutionary nutrition package (high quality diet plus nutrition messaging); and 2) control (standard-of care supplements). Ultrasound brain measures, nutrition and morbidity data, and blood metabolomics will be assessed at 21 weeks gestational age, 37 weeks gestational stage, and postpartum. This pilot study uniquely combines the expertise of multiple disciplines - public health nutrition, radiology, neuroscience, and metabolomics - to examine the potential for improved nutrition on early growth and brain development with vital public health implications.
Read the detailed description
The pilot trial will be conducted in the highlands of Ecuador in a mixed indigenous and non-indigenous population of pregnant women. Nationally, the stunting prevalence among young children is 25.3%, but large disparities within the country especially indigenous communities where stunting prevalence is nearly double, 42.3% (Freire et al., 2014). Incidence of low birthweight (8%) also varies by population in Ecuador, and may represent in utero growth restriction (IUGR) and other harmful exposures during pregnany (UNICEF 2012). While a large proportion of women have at least one antenatal care visit (84%), Only 58% of women in Ecuador meet the the WHO recommended 4+ antenatal care visits. This pilot project will leverage learnings from the Lulun Project and a previous antenatal health study (Gallegos et al. 2017) to design a social marketing campaign that encourages participation and high compliance. For this pilot RCT, the investigators will recruit pregnant women accessing antenatal care from Centro de Salud El Quinche in Pichincha province. Our target population will include those from poor households in particular (who access free public health services) with higher risks for IUGR and undernutrition during pregnancy.
The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes. In order to adapt the food groups to the Ecuador context, the investgators first developed a list of foods appropriate for the Ecuador context within each food group (Table 1). The food list draws on evidence from the Ministry of Health in Ecuador and USFQ for commonly consumed foods, notably among indigneous populations (Gallegos et al. 2010). Criteria for the full list of foods were the following: culturally appropriate; economically affordable and accessible; and environmentally sustainable. As was the experience with eggs in the Lulun Project, application of these criteria better ensure translation of findings within communities in the future.
Pregnant women will be recruited during first trimester of pregnancy and randomized to intervention group (EN plate + nutrition messaging + standard of care supplements) or control group (standard of care supplements). The intervention period will occur during second and third trimesters. Food supplies sufficient for one EN plate per day for 7 days will be delivered to pregnant women on a weekly basis. Under the supervision of the nutrition-trained field director, foods from each food group in pre-specified nutrient proportions will be secured from local food producers. Consideration will be given to including foods that do not require refrigeration over a one-week period. Careful documentation will be made of the foods contained in the weekly box in order to calculate exact quantity of nutrients provided. Due to concerns about food sharing that were evident in our qualitative research findings, additional food supplies will be provided for other household members in a separate container. Suggested menus and recipes will be provided with each delivery depending on the included foods.
Nutrition messages, developed in tandem with the social marketing campaign described below, will emphasize the importance of the food provisions for the participating pregnant women, but communicate the value of the EN plate for all household members. Messaging each week will reinforce the importance of eliminating ultraprocessed foods from the diet and reducing rice consumption. The absence of ultra processed foods is integral to our hypothesized effect and critical for confronting the dual burden of over- and under-nutrition in Ecuador (Freire et al. 2014). During each weekly food delivery visit, data will be collected on adherence and morbidities.
- Conditions
- Growth Disorders, Malnutrition, Fetal, Stunting, Development; Delayed, Malnutrition, Nutrition Disorder, Fetal, Maternal Nutritional Disorders Affecting Fetus or Newborn
- Being tested
- Evolutionary Nutrition Package
- Medical subject headings
- Growth Disorders, Fetal Nutrition Disorders, Malnutrition
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Evolutionary Nutrition PackageOther
The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes.
| Study group | Role | What they receive |
|---|---|---|
| Experimental Group | Experimental | Receives evolutionary nutrition package [high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)] Receives: Other: Evolutionary Nutrition Package |
| Control Group | No intervention | Receives standard-of-care, iron-folic acid and calcium supplements. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Length-for-age Z (LAZ)
LAZ is a measure of stunting, whether a child is the appropriate length/height for their age
Measured: 6 months
Plasma concentrations of Docosahexaenoic acid (DHA)
Plasma concentration of DHA measured in µg/mL
Measured: 6 months
Plasma concentrations of Linoleic acid (LA)
Plasma concentration of LA measured in µg/mL
Measured: 6 months
Plasma concentrations of α-Linoleic acid (ALA)
Plasma concentration of ALA measured in µg/mL
Measured: 6 months
Plasma concentrations of Betaine
Plasma concentration of Betaine measured in µg/mL
Measured: 6 months
Plasma concentrations of Methionine
Plasma concentration of Methionine measured in µg/mL
Measured: 6 months
Plasma Concentration of Choline
Plasma concentration of Choline measured in µg/mL
Measured: 6 months
Plasma Concentration of Iron (Fe)
Plasma concentration of Iron (Fe) measured in mg/mL
Measured: 6 months
Plasma Concentration of Zinc (Zn)
Plasma concentration of Zinc (Zn) measured in mg/mL
Measured: 6 months
Plasma Concentration of Selenium (Se)
Plasma concentration of Selenium (Se) measured in mg/mL
Measured: 6 months
Brain structure development--Gangliothalamic ovoid (GTO) volume
GTO volume measured in cm3
Measured: 4 months
Brain structure development--Gangliothalamic ovoid (GTO) diameter
GTO diameter measured in cm
Measured: 4 months
Brain structure development--Gangliothalamic ovoid (GTO) craniocaudal
GTO craniocaudal measured in cm
Measured: 4 months
Brain structure development-- thalamic diameter
Thalamic diameter in cm
Measured: 4 months
Secondary outcomes (1)
Maternal Morbidity
Rate of morbidities common during pregnancy including anemia, urinary tract infections, hypertension, gestational diabetes, respiratory infections, and hyperemesis gravidarum.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Feb 2022
- Study start5 Jan 2022
- Primary completion1 Aug 2024
- Study completionJun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Growth DisordersStudies of the same condition, open and under way.
- More trials run by Washington University School of MedicineThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Washington University School of Medicine
- Sponsor type
- University, hospital or other
- Collaborators
- Children's Discovery Institute, Universidad San Francisco de Quito, St. Louis Children's Hospital
- Responsible party
- Sponsor
- Investigators
- Ivan Palacios, MD, Study director, Universidad San Francisco de Quito
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05242224
- Sponsor's protocol ID
- 2019-044E
- Status last verified
- Oct 2024
- First submitted
- 28 Jun 2019
- Last updated
- 28 Oct 2024
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evolutionary Nutrition Pilot: Enhancing Fetal Growth and Brain Development
- ClinicalTrials.gov ID
- NCT05242224
- Acronym / sponsor ID
- 2019-044E
- Conditions
- Growth Disorders, Malnutrition, Fetal, Stunting, Development; Delayed, Malnutrition, Nutrition Disorder, Fetal, Maternal Nutritional Disorders Affecting Fetus or Newborn
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Washington University School of MedicineUniversity, hospital or other
- Collaborators
- Children's Discovery Institute, Universidad San Francisco de Quito, St. Louis Children's Hospital
- Study start
- 5 Jan 2022 (actual)
- Primary completion
- 1 Aug 2024 (actual)
- Study completion
- Jun 2025 (estimated)
- First posted
- 16 Feb 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Globally, 250 million children do not reach their developmental potential and 155 million are stunted, yet few population-based studies have examined the direct effects of nutrient deficiencies on early brain development. This study will examine an evolutionary nutrition intervention during pregnancy derived from diets consumed for 99.9% of hominin history when bodies and brains were healthier. A pilot clinical trial will be conducted in the central highlands of Ecuador to compare fetal and newborn outcomes among women randomized to: 1) evolutionary nutrition package (high quality diet plus nutrition messaging); and 2) control (standard-of care supplements). Ultrasound brain measures, nutrition and morbidity data, and blood metabolomics will be assessed at 21 weeks gestational age, 37 weeks gestational stage, and postpartum. This pilot study uniquely combines the expertise of multiple disciplines - public health nutrition, radiology, neuroscience, and metabolomics - to examine the potential for improved nutrition on early growth and brain development with vital public health implications.
Detailed description
The pilot trial will be conducted in the highlands of Ecuador in a mixed indigenous and non-indigenous population of pregnant women. Nationally, the stunting prevalence among young children is 25.3%, but large disparities within the country especially indigenous communities where stunting prevalence is nearly double, 42.3% (Freire et al., 2014). Incidence of low birthweight (8%) also varies by population in Ecuador, and may represent in utero growth restriction (IUGR) and other harmful exposures during pregnany (UNICEF 2012). While a large proportion of women have at least one antenatal care visit (84%), Only 58% of women in Ecuador meet the the WHO recommended 4+ antenatal care visits. This pilot project will leverage learnings from the Lulun Project and a previous antenatal health study (Gallegos et al. 2017) to design a social marketing campaign that encourages participation and high compliance. For this pilot RCT, the investigators will recruit pregnant women accessing antenatal care from Centro de Salud El Quinche in Pichincha province. Our target population will include those from poor households in particular (who access free public health services) with higher risks for IUGR and undernutrition during pregnancy.
The evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes. In order to adapt the food groups to the Ecuador context, the investgators first developed a list of foods appropriate for the Ecuador context within each food group (Table 1). The food list draws on evidence from the Ministry of Health in Ecuador and USFQ for commonly consumed foods, notably among indigneous populations (Gallegos et al. 2010). Criteria for the full list of foods were the following: culturally appropriate; economically affordable and accessible; and environmentally sustainable. As was the experience with eggs in the Lulun Project, application of these criteria better ensure translation of findings within communities in the future.
Pregnant women will be recruited during first trimester of pregnancy and randomized to intervention group (EN plate + nutrition messaging + standard of care supplements) or control group (standard of care supplements). The intervention period will occur during second and third trimesters. Food supplies sufficient for one EN plate per day for 7 days will be delivered to pregnant women on a weekly basis. Under the supervision of the nutrition-trained field director, foods from each food group in pre-specified nutrient proportions will be secured from local food producers. Consideration will be given to including foods that do not require refrigeration over a one-week period. Careful documentation will be made of the foods contained in the weekly box in order to calculate exact quantity of nutrients provided. Due to concerns about food sharing that were evident in our qualitative research findings, additional food supplies will be provided for other household members in a separate container. Suggested menus and recipes will be provided with each delivery depending on the included foods.
Nutrition messages, developed in tandem with the social marketing campaign described below, will emphasize the importance of the food provisions for the participating pregnant women, but communicate the value of the EN plate for all household members. Messaging each week will reinforce the importance of eliminating ultraprocessed foods from the diet and reducing rice consumption. The absence of ultra processed foods is integral to our hypothesized effect and critical for confronting the dual burden of over- and under-nutrition in Ecuador (Freire et al. 2014). During each weekly food delivery visit, data will be collected on adherence and morbidities.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Experimental Group | Experimental | Other: Evolutionary Nutrition PackageReceives evolutionary nutrition package [high quality diet plus nutrition messaging + standard of care (iron-folic acid and calcium supplements)] |
| Control Group | No intervention | –Receives standard-of-care, iron-folic acid and calcium supplements. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- healthy
- in their first trimester
- carrying a singleton pregnancy
Key exclusion criteria (6 listed)
- less than 18 years of age
- have a chronic health condition (HIV, TB, epilepsy, etc.)
- have a multiple pregnancy (twins, triplets, etc.)
- intend to move away from the study area
- have known allergies to eggs or fish
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Evolutionary Nutrition PackageThe evolutionary nutrition package includes two key components: 1) one full meal per day from the evolutionary nutrition (EN) plate; 2) targeted messaging for high quality nutrition and removal of ultra-processed foods from the diet. The EN plate includes five food groups identified from the literature on evolutionary diets: animal source foods (ASF); berries and other fruits; tubers; vegetables, herbs and spices; and nuts and other legumes. | Other | Experimental Group |
Primary outcome
Length-for-age Z (LAZ)
Time frame: 6 months
LAZ is a measure of stunting, whether a child is the appropriate length/height for their age
Plasma concentrations of Docosahexaenoic acid (DHA)
Time frame: 6 months
Plasma concentration of DHA measured in µg/mL
Plasma concentrations of Linoleic acid (LA)
Time frame: 6 months
Plasma concentration of LA measured in µg/mL
Plasma concentrations of α-Linoleic acid (ALA)
Time frame: 6 months
Plasma concentration of ALA measured in µg/mL
Plasma concentrations of Betaine
Time frame: 6 months
Plasma concentration of Betaine measured in µg/mL
Plasma concentrations of Methionine
Time frame: 6 months
Plasma concentration of Methionine measured in µg/mL
Plasma Concentration of Choline
Time frame: 6 months
Plasma concentration of Choline measured in µg/mL
Plasma Concentration of Iron (Fe)
Time frame: 6 months
Plasma concentration of Iron (Fe) measured in mg/mL
Plasma Concentration of Zinc (Zn)
Time frame: 6 months
Plasma concentration of Zinc (Zn) measured in mg/mL
Plasma Concentration of Selenium (Se)
Time frame: 6 months
Plasma concentration of Selenium (Se) measured in mg/mL
Brain structure development--Gangliothalamic ovoid (GTO) volume
Time frame: 4 months
GTO volume measured in cm3
Brain structure development--Gangliothalamic ovoid (GTO) diameter
Time frame: 4 months
GTO diameter measured in cm
Brain structure development--Gangliothalamic ovoid (GTO) craniocaudal
Time frame: 4 months
GTO craniocaudal measured in cm
Brain structure development-- thalamic diameter
Time frame: 4 months
Thalamic diameter in cm
1 secondary outcome
Maternal Morbidity
Time frame: 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2024.
Related trials for Growth Disorders
Active, not recruitingPhase 3
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
Non-small Cell Lung Cancer (NSCLC)
RecruitingPhase 1
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Solid Tumor, Advanced Solid Tumor
Active, not recruitingPhase 3
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
Carcinoma, Non-Small-Cell Lung
RecruitingObservational study
Children s Growth and Behavior Study
Obesity, Eating Behaviors
Active, not recruitingPhase 3
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
Non-small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ivan Palacios, MD study director
Universidad San Francisco de Quito
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Evolutionary Nutrition Package in people with Growth Disorders and Malnutrition, Fetal, run by Washington University School of Medicine at 1 site in Ecuador.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 28 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ecuador. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Length-for-age Z (LAZ) (time frame: 6 months). The study lists 14 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2024.